Evidence map›Paper›PMID 41599726›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

State of the Art and Development Trends in Obtaining Fast-Dissolving Forms of Creatine Monohydrate.

Sabr A Albagachiev, Elizaveta D Pinegina, Ivan A Sadkovskii, Ivan I Krasnyuk, Mark A Mandrik

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sabr A AlbagachievA.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0009-0003-5489-7001
Elizaveta D PineginaA.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0009-0001-7890-0821
Ivan A SadkovskiiA.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0000-0001-8375-9909
Ivan I KrasnyukA.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0000-0002-7242-2988
Mark A MandrikA.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0000-0002-3558-9615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Creatine monohydrate is known for its moderate solubility (13 g/L at 25 °C), which limits the feasibility of producing its fast-dissolving forms. Overcoming this limitation is possible through the application of technological approaches, the overview of which is presented in this work, including chemical modification, micronization, granulation, amorphization, formation of solid dispersions, and encapsulation. The results showed the predominance of chemical methods (about 60% of the analyzed patents). At the same time, the use of physical methods and the combination of several technologies can increase both the dissolution rate and the solubility of creatine monohydrate while maintaining its stability. This makes these approaches the most promising for the development of production technology for fast-dissolving forms.

Indexed as

creatine monohydratefast-dissolving creatinemodified creatinepatent studiessolubility enhancement methods

Identifiers

PMID41599726
PMCPMC12845340

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.